Alterity Therapeutics Limited (ATHE): Price and Financial Metrics
GET POWR RATINGS... FREE!
ATHE Stock Price Chart Interactive Chart >
ATHE Price/Volume Stats
| Current price | $3.91 | 52-week high | $10.50 |
| Prev. close | $3.81 | 52-week low | $2.90 |
| Day low | $3.80 | Volume | 25,900 |
| Day high | $3.97 | Avg. volume | 23,439 |
| 50-day MA | $3.59 | Dividend yield | N/A |
| 200-day MA | $5.33 | Market Cap | 15.68M |
Alterity Therapeutics Limited (ATHE) Company Bio
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.
Latest ATHE News From Around the Web
Below are the latest news stories about ALTERITY THERAPEUTICS LTD that investors may wish to consider to help them evaluate ATHE as an investment opportunity.
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System AtrophyRecruitment ongoing in Europe, Asia-Pacific, and the U.S. for study of rapidly progressive Parkinsonian DisorderMELBOURNE, Australia AND SAN FRANCISCO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company’s Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) |
Is Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year?Here is how Vir Biotechnology, Inc. (VIR) and Prana Biotechnology Ltd (ATHE) have performed compared to their sector so far this year. |
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System AtrophyAlterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrollment at Vanderbilt University Medical Center in Nashville, Tennessee. |
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation)Alterity Therapeutics Limited ("Alterity" or the "Company") (ASX:ATH, NASDAQ:ATHE), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that its Board of Directors approved a ratio change of its American Depository Shares (ADSs) to Ordinary Shares (the "ADS Ratio") from the current ADS Ratio of 1 ADS representing 60 Ordinary Shares to 1 ADS representing 600 Ordinary Shares (the "ADS Ratio Change"). The ADS Ratio Change will |
Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation ForumAlterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (NIF). The forum is taking place Sunday, January 8, 2022, as part of the activities surrounding the annual J.P. Morgan Healthcare Conference. |
ATHE Price Returns
| 1-mo | 13.33% |
| 3-mo | -2.86% |
| 6-mo | -34.27% |
| 1-year | -53.40% |
| 3-year | -50.42% |
| 5-year | -85.88% |
| YTD | 12.29% |
| 2022 | -51.64% |
| 2021 | -46.27% |
| 2020 | 71.79% |
| 2019 | -39.06% |
| 2018 | -58.97% |
Loading social stream, please wait...